Role of SGLT2 inhibitors in the treatment of visceral obesity

Role of SGLT2 inhibitors in the treatment of visceral obesity

The increasing prevalence of obesity limits the prevention of the development and progression of chronic non-communicable diseases. The central methods of risk correction associated with obesity are lifestyle changes and prescribing medications for obesity. Sodium-glucose co-transporter type-2 (SGLT...

Full description

Saved in:

Bibliographic Details
Main Authors:	M. A. Druzhilov, T. Yu. Kuznetsova
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2021-02-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	visceral obesity sodium-glucose co-transporter type-2 gliflozins cardio-renal-metabolic risk
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/2648
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A New Chapter in the Treatment of Patients with Heart Failure. The Role of Sodium-Glucose Co-transporter Type 2 Inhibitors
by: D. P. Golubovskaya, et al.
Published: (2022-11-01)

Promising areas of pharmacotherapy for obesity
by: M. A. Druzhilov, et al.
Published: (2021-04-01)

Cardio–Renal and Systemic Effects of SGLT2i Dapagliflozin on Short-Term Anthracycline and HER-2-Blocking Agent Therapy-Induced Cardiotoxicity
by: Vincenzo Quagliariello, et al.
Published: (2025-05-01)

Heterogeneity of obesity phenotypes in relation to cardiovascular risk
by: М. A. Druzhilov, et al.
Published: (2019-03-01)

VISCERAL ADIPOSITY AS A GLOBAL FACTOR OF CARDIOVASCULAR RISK
by: G. A. Chumakova, et al.
Published: (2018-06-01)

Prediction Value of Visceral Obesity Related Indices for Visceral Obesity in Chinese Patients with Type 2 Diabetes Mellitus
by: Tan Y, et al.
Published: (2025-06-01)

Advances in the mechanism of action of SGLT2 inhibitors on the kidney
by: JI Ying, et al.
Published: (2020-01-01)

Multiagonists of the “incretin axis” as a promising tool for managing cardiometabolic risk in visceral obesity
by: M. A. Druzhilov, et al.
Published: (2022-05-01)

Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents
by: E. R. Radkevich, et al.
Published: (2025-05-01)

New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia
by: Cheng-Hsien Hung, et al.
Published: (2024-12-01)

Triglyceride-glucose index as a marker for visceral obesity in patients with gastric cancer
by: Junbo Zuo, et al.
Published: (2025-01-01)

Prepregnancy body mass index and visceral fat exhibit divergent associations with metabolic factors in pregnant women with obesity: A Norwegian cohort study
by: Maja Lecic Bonnichsen, et al.
Published: (2024-12-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

Predictive Accuracy of Biochemical and Anthropometric Indices for Metabolic Syndrome in Children with Obesity: A Comparative Study
by: Cihad Dundar
Published: (2025-01-01)

Sodium-Dependent Glucose Transporter Type 2 Inhibitors as a Breakthrough in Neutropenia and Neutrophil Dysfunction Management in Patients with Glycogen Storage Disease Type Ib
by: Andrey N. Surkov, et al.
Published: (2024-07-01)

OPPORTUNITIES FOR THE USE OF VISCERAL OBESITY INDEX IN METABOLIC SYNDROME DIAGNOSTICS AND PROGNOSIS OF ITS COMPLICATION RISK
by: R. A. Libis, et al.
Published: (2014-09-01)

Visceral Obesity: Terminology, Measurement, and Its Correlation with Inflammation
by: Anna A. Tarabrina, et al.
Published: (2022-10-01)

Study of Cardio-Metabolic Risk in Overweight and Obese People with Impaired Vitamin D Status
by: Maria Nikolova, et al.
Published: (2024-01-01)

Strategies and methods for the correction of obesity and associated cardiovascular risk
by: T. Yu. Kuznetsova, et al.
Published: (2019-05-01)

METHODS OF VISCERAL OBESITY ASSESSMENT IN CLINICAL PRACTICE
by: G. A. Chumakova, et al.
Published: (2016-04-01)

RISK ASSESSMENT MODEL FOR CORONARY ATHEROSCLEROSIS IN PATIENTS WITH VISCERAL OBESITY
by: N. G. Veselovskaya, et al.
Published: (2015-04-01)

Epicardial adipose tissue thickness as a possible predictor of carotid atherosclerosis in patients with abdominal obesity
by: M. A. Druzhilov, et al.
Published: (2021-04-01)

“Obesity paradoxes”: main causes of an “inverse” cardiovascular epidemiology
by: M. A. Druzhilov, et al.
Published: (2018-10-01)

Sex-specific differences in the efficacy of renal denervation in patients with resistant hypertension depending on visceral obesity and kidney function
by: Irina Zyubanova, et al.
Published: (2025-01-01)

Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE−2 study
by: Cesare Berra, et al.
Published: (2024-12-01)

PREDICTIVE SIGNIFICANCE OF ARTERIAL STIFFNESS PARAMETERS IN EVALUATION OF CARDIOMETABOLIC RISK IN OBESITY PATIENTS
by: O. Yu. Druzhilova, et al.
Published: (2018-06-01)

Association of novel visceral obesity indices with 10-year risk of major cardiovascular events in patients with type 2 diabetes mellitus
by: Mirella Y. Tawfik, et al.
Published: (2025-05-01)

Long-term effects of SGLT2 inhibitors on arrhythmias: a systematic review and meta-analysis
by: Peipei Li, et al.
Published: (2025-07-01)

Associations of renal sinus fat with metabolic parameters, abdominal visceral adipose tissue, metabolic syndrome, fructose intake, and blood pressure control in obese individuals with hypertension: a cross-sectional study
by: Paniz Anvarifard, et al.
Published: (2024-01-01)

Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis
by: Hamed Hajishah, et al.
Published: (2025-08-01)

Effect of Orlistat Treatment on Visceral Adiposity Index (VAI) in Obese Patients
by: İhsan Solmaz, et al.
Published: (2025-06-01)

Sodium-glucose co-transporter-2 inhibitors in heart failure and chronic kidney disease: the role of empagliflozin
by: M. M. Batyushin
Published: (2021-04-01)

Algorithm for radiological examination of visceral obesity in patients with metabolic syndrome
by: N. M. Suslyayeva, et al.
Published: (2012-10-01)

EFFICACY OF SGLT-2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES: SINGLE CENTRE EXPERIENCE
by: Ramazan Çakmak, et al.
Published: (2025-01-01)

CLINICAL APPLICATION OF QUANTITATIVE ECHOCARDIOGRAPHIC ASSESSMENT OF EPICARDIAL FAT TISSUE IN OBESITY
by: T. Yu. Kuznetsova, et al.
Published: (2017-05-01)

Impact of visceral obesity on postoperative outcomes in colorectal cancer: a systematic review and meta-analysis
by: Yulong Wang, et al.
Published: (2025-05-01)

SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
by: Vladimir V Salukhov, et al.
Published: (2021-01-01)

Current applications and prospects of visceral fat in obesity diagnosis and comorbidity prediction
by: ZHANG Yifei, SHI Juan, XU Yuening
Published: (2025-02-01)

The impacts of SGLT2 inhibitors on the mortality of patients with tuberculosis
by: Chung-Shu Lee, et al.
Published: (2025-05-01)

Effect of visceral obesity on main artery elasticity and vascular age in patients with hypertension, obesity, and type 2 diabetes
by: M. E. Statsenko, et al.
Published: (2021-05-01)